Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 99, Issue 2, Pages 362-372Publisher
WILEY-LISS
DOI: 10.1002/jcb.20811
Keywords
androgen receptor; prostate cancer; co-activator; cell signaling
Categories
Funding
- NCI NIH HHS [CA58204] Funding Source: Medline
- NIDDK NIH HHS [DK65252] Funding Source: Medline
Ask authors/readers for more resources
The importance of androgens and androgen receptors (AR) in primary prostate cancer is well established. Metastatic disease is usually treated with some form of androgen ablation, which is effective for a limited amount of time. The role of AR in prostate cancers that recur despite androgen ablation therapy is less certain. Most of these tumors express prostate specific antigen (PSA), an androgen-regulated gene; moreover, AR is generally highly expressed in recurrent prostate cancer. We propose that AR continues to play a role in many of these tumors and that it is not only the levels of AR, ligands, and co-regulators, but also the changes in cell signaling that induce AR action in recurrent prostate cancer. These pathways are, therefore, potential therapeutic targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available